GLP-1 agonists are drugs developed to act analogously to glucagon-like peptide, by binding to the same receptor on pancreatic beta cells they increase the release of insulin
You are not fighting nausea at your desk or trying to eat a business lunch when food repulses you
GLP-1 receptor agonists carry recognised adverse effects that must be weighed against any potential benefits: Gastrointestinal symptoms (nausea, vomiting, diarrhoea) occur commonly, particularly during dose escalation Risk of pancreatitis , though rare, requires clinical vigilance
A diagnosis of depressive disorder was also reported in 20% of the cohort
It helps boost energy, improve hydration, enhance immunity, and support overall health and wellness
These affordability measures are essential in ensuring continuity of care and improving therapeutic outcomes